Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Exelixis and CSL Limited Sponsored ADR are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. This means that EXEL's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. However, value investors will care about much more than just this.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

EXEL currently has a forward P/E ratio of 18.06, while CSLLY has a forward P/E of 26.41. We also note that EXEL has a PEG ratio of 0.77. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CSLLY currently has a PEG ratio of 1.80.

Another notable valuation metric for EXEL is its P/B ratio of 4.35. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, CSLLY has a P/B of 4.42.

Based on these metrics and many more, EXEL holds a Value grade of B, while CSLLY has a Value grade of C.

EXEL has seen stronger estimate revision activity and sports more attractive valuation metrics than CSLLY, so it seems like value investors will conclude that EXEL is the superior option right now.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL) : Free Stock Analysis Report

CSL Limited Sponsored ADR (CSLLY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research